ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 9

Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

November 12, 2024

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Christine Bestvina, MD, University of Chicago, Hatim Husain, MD, Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center, Julia K. Rotow, MD

This episode discusses the impressive ORR of more than 40% from the phase 2 TROPION-Lung05 trial of Dato-DXd in patients with EGFR-mutated advanced NSCLC, its clinical impact on those treated with 3 or more prior therapies, and explores the potential of Dato-DXd as a practice-changing therapy, given the median DOR of 7 months and DCR of 79%.

EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

Now Viewing

EP. 9: Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP. 10: Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP. 11: Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP. 12: Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

EP. 13: Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

EP. 14: Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

Video content above is prompted by the following:

From the primary results of the phase 2 TROPION-Lung05 trial, please share your impressions of the ORR of greater than 40% among patients with EGFR-mutated advanced or metastatic NSCLC.
From a clinical practice perspective, how impactful is this response rate, particularly among patients who had received 3or more lines of prior therapy?